Ophthalmology Doctors in Harbor City, CA Accepting Medicare

8 Ophthalmology doctors found. Showing 1 - 8

Kenneth A. Feldman, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 310-325-5111

Jasmine Simone Hayes-adams, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 310-325-5111

Teddy Y. Tong, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 310-325-5111

Mamdouh L. Nakla, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 310-325-5111

Alexander H. Tu, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 310-325-5111

John C. Terrell, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 310-325-5111

Nader Ameli, DO Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 310-325-5111

Harvey A. Brown, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 310-325-5111

News Archive

Alnylam Pharmaceuticals earns $20M technology transfer payment from Takeda Pharmaceutical

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has earned a $20 million technology transfer payment from Takeda Pharmaceutical Company Limited as part of the strategic alliance the companies formed in May 2008.

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

Understanding immune system's balancing act could help in prevention, treatment of IBD

Australian researchers have uncovered clues in the immune system that reveal how the balance of 'good' gut bacteria is maintained. This information could help in the prevention and treatment of inflammatory bowel disease.

Massachusetts support of stem cell research

The Massachusetts Medical Society, the statewide association of physicians with some 18,000 members, has offered testimony before the Joint Committee on Economic Development and Emerging Technologies in support of Senate Bill 25, An Act Promoting Stem Cell Research.

Read more Medical News

› Verified 7 days ago